TB-HAART trial

Affiliations

¹ Department of Infectious Diseases, Austin Health, Heidelberg, Victoria 3084, Australia. Electronic address: kwongj@gmail.com.
² Department of Infectious Diseases, Austin Health, Heidelberg, Victoria 3084, Australia.

Comment

Jason C Kwong et al. Lancet Infect Dis. 2015 Jan.

. 2015 Jan;15(1):14-5.

doi: 10.1016/S1473-3099(14)71032-1.

¹ Department of Infectious Diseases, Austin Health, Heidelberg, Victoria 3084, Australia. Electronic address: kwongj@gmail.com.
² Department of Infectious Diseases, Austin Health, Heidelberg, Victoria 3084, Australia.

No abstract available

Comment in

TB-HAART trial--authors' reply.
Mfinanga SG, Kirenga BJ, Chanda DM, Connolly C, Mwaba P, Joloba M, Zumla A; TB-HAART Study Group. Mfinanga SG, et al. Lancet Infect Dis. 2015 Jan;15(1):15-6. doi: 10.1016/S1473-3099(14)71051-5. Lancet Infect Dis. 2015. PMID: 25541163 No abstract available.

Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
Mfinanga SG, Kirenga BJ, Chanda DM, Mutayoba B, Mthiyane T, Yimer G, Ezechi O, Connolly C, Kapotwe V, Muwonge C, Massaga J, Sinkala E, Kohi W, Lyantumba L, Nyakoojo G, Luwaga H, Doulla B, Mzyece J, Kapata N, Vahedi M, Mwaba P, Egwaga S, Adatu F, Pym A, Joloba M, Rustomjee R, Zumla A, Onyebujoh P. Mfinanga SG, et al. Lancet Infect Dis. 2014 Jul;14(7):563-71. doi: 10.1016/S1473-3099(14)70733-9. Epub 2014 May 5. Lancet Infect Dis. 2014. PMID: 24810491 Clinical Trial.